Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

IULILIA BURMISTROVA -- GETTY IMAGES Dec 9, 2024 56 mins ago ...

They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...

The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...

The published evidence identified also showed that insulin administration via NovoPen ® devices was for most patients easier, more convenient and quicker than with conventional syringes and that ...

What Are GLP-1s? Glucagon-like peptide-1 receptor agonists, also known as GLP-1 drugs, are a class of medications that mimic the action of ...

Nov. 25, 2024 — The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in ...

Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.